Engineering a human neuroimmune specific viral vector from Zika virus
Project Number5R21EB034970-02
Contact PI/Project LeaderBARTELLE, BENJAMIN B
Awardee OrganizationARIZONA STATE UNIVERSITY-TEMPE CAMPUS
Description
Abstract Text
PROJECT SUMMARY
Inflammation has been implicated in nearly every neuropsychiatric and degenerative disease,
yet neuroimmune cells remain nearly intractable by every available therapeutic strategy. Small
molecule drugs consistently fail clinical trials, as neuroimmune signaling pathways have essential
pleiotropic functions in neighboring cell types. Meanwhile cell type selective therapies remain elusive,
as microglia, and other neuroimmune cells, are intrinsically resistant to gene therapy vectors.
Overcoming these unique challenges demands a new approach to medicine, drawing from an unlikely
source of neuroimmune specific bioactivity.
In nature, the Zika virus (ZKV) infects microglia, suppresses inflammation, and stimulates
autophagy so expertly that almost half of infections go unnoticed. If this bioactivity could be safely
refined, it would offer relief for neurodegenerative disorders from Parkinson’s to Alzheimer's disease.
Parsing therapeutic from pathogenic mechanisms of the ZKV genome presents much greater
complexity than ever previously addressed, but recent advances make it possible. Recombinant ZKV
vectors, already in use, provide starting material for synthetic biology, while new viral assisted and
continuous evolution methods allow bioengineering at scales capable of reshaping whole genomes.
We can harness ZKV’s microglia specific immunosuppressive mechanisms into therapies with
potential beyond any current technology. This proposal presents the first steps along the path
towards an entirely new kind of therapy for neurodegenerative disorders.
Public Health Relevance Statement
PROJECT NARRATIVE:
Viruses have been engineered into invaluable tools for research and vehicles for therapeutics,
but none effectively reach neuroimmune cells. The Zika virus offers a host of mechanisms to
selectively target and suppress the intrinsic and innate immune responses of microglia, the
predominant immune cell. We propose the domestication of Zika into a neuroimmune selective vector
and a platform for tailored immunomodulation. The bioactivity can be harnessed into root cause
therapies for the treatment of neuroinflammatory and degenerative diseases.
National Institute of Biomedical Imaging and Bioengineering
CFDA Code
286
DUNS Number
943360412
UEI
NTLHJXM55KZ6
Project Start Date
07-July-2023
Project End Date
30-April-2026
Budget Start Date
01-May-2024
Budget End Date
30-April-2025
Project Funding Information for 2024
Total Funding
$183,518
Direct Costs
$125,000
Indirect Costs
$58,518
Year
Funding IC
FY Total Cost by IC
2024
National Institute of Biomedical Imaging and Bioengineering
$183,518
Year
Funding IC
FY Total Cost by IC
Sub Projects
No Sub Projects information available for 5R21EB034970-02
Publications
Publications are associated with projects, but cannot be identified with any particular year of the project or fiscal year of funding. This is due to the continuous and cumulative nature of knowledge generation across the life of a project and the sometimes long and variable publishing timeline. Similarly, for multi-component projects, publications are associated with the parent core project and not with individual sub-projects.
No Publications available for 5R21EB034970-02
Patents
No Patents information available for 5R21EB034970-02
Outcomes
The Project Outcomes shown here are displayed verbatim as submitted by the Principal Investigator (PI) for this award. Any opinions, findings, and conclusions or recommendations expressed are those of the PI and do not necessarily reflect the views of the National Institutes of Health. NIH has not endorsed the content below.
No Outcomes available for 5R21EB034970-02
Clinical Studies
No Clinical Studies information available for 5R21EB034970-02
News and More
Related News Releases
No news release information available for 5R21EB034970-02
History
No Historical information available for 5R21EB034970-02
Similar Projects
No Similar Projects information available for 5R21EB034970-02